Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer

Outlook names a proven retina launch executive as CCO ahead of LYTENAVA's U.S. debut.

What the company is saying

Outlook Therapeutics has appointed Greg DiPasquale as Chief Commercial Officer, emphasizing his extensive track record in retina product launches and commercial leadership. The company highlights that DiPasquale joined as Head of Commercial for LYTENAVA in December 2025 and now leads all commercial functions as Outlook prepares to make LYTENAVA available to eligible U.S. patients before the end of 2026. The announcement underscores LYTENAVA’s status as the first and only FDA-approved ophthalmic formulation of bevacizumab for wet AMD, and notes its regulatory approvals in the EU and UK. DiPasquale’s prior roles included leading national sales for a Regeneron retina portfolio generating approximately $6 billion in annual revenue, and launching BEOVU at Novartis. The company’s messaging is confident, positioning DiPasquale’s leadership as central to a successful U.S. launch and leveraging his relationships in the retina community. The release also details his academic credentials and ongoing role at Ohio University, reinforcing his industry credibility. The company frames the upcoming U.S. launch as a near-term, concrete operational milestone.

What the data suggests

The announcement provides hard facts on executive experience, regulatory milestones, and product safety, but limited financial data for Outlook itself. DiPasquale’s leadership of a $6 billion annual revenue portfolio at Regeneron demonstrates relevant scale, though this figure is not directly tied to Outlook’s current or projected performance. LYTENAVA is confirmed as FDA-approved in the U.S. and has received marketing authorizations in the EU and UK, with commercial launches already commenced in Germany, Austria, and the UK. The company discloses that LYTENAVA will be made available to eligible U.S. patients before the end of 2026, a timeline that is now less than three months away. Adverse reaction rates for LYTENAVA are specified: conjunctival hemorrhage (4%), eye pain (2%), and vitreous floaters (2%), with a reporting threshold of ≥1%. There is no disclosure of Outlook’s own revenue, launch costs, or sales projections, so the financial trajectory remains unclear. The data set is robust on personnel and regulatory progress but incomplete on commercial performance.

Analysis

This announcement is primarily a personnel update, disclosing the appointment of a new Chief Commercial Officer and summarizing his relevant experience. The tone is positive, emphasizing Mr. DiPasquale's track record and the company's preparations for a U.S. launch of LYTENAVA before the end of 2026. Most claims are factual and realized, such as regulatory approvals in the U.S., EU, and UK, and the commencement of commercial launch in Germany, Austria, and the UK. Only one key claim is forward-looking: the planned U.S. commercial availability by end-2026, which is a near-term milestone. There is no evidence of exaggerated language or narrative inflation, and no large capital outlay or financial projections are discussed. The announcement does not overstate progress or benefits, and the absence of financial metrics is appropriate for a personnel release.

Risk flags

• ●The success of LYTENAVA’s U.S. launch depends on rapid execution and market adoption within a tight timeframe, with less than three months until the stated availability target. Any delays or missteps could impact revenue generation and investor confidence.
• ●There is a dependency on a single executive, Greg DiPasquale, to lead all commercial functions, which concentrates key operational risk in one individual. While his track record is strong, unforeseen changes in leadership or performance could disrupt launch momentum.
• ●The absence of disclosed financial projections or early sales data for LYTENAVA means investors have no visibility into expected revenue, profitability, or launch costs. This limits the ability to assess commercial risk or upside.

Bottom line

This announcement signals that Outlook Therapeutics is entering the final phase before LYTENAVA’s U.S. launch, with a seasoned retina executive now formally leading commercialization. The regulatory groundwork is complete, and the product is already being sold in select European markets, but the U.S. launch is the key near-term catalyst. DiPasquale’s experience with multi-billion-dollar retina portfolios adds credibility, but there is no direct evidence yet of LYTENAVA’s commercial traction or revenue potential. Investors should focus on whether the company meets its end-of-2026 U.S. launch target and how quickly it can demonstrate sales momentum. The most important takeaway is that execution over the next quarter will determine whether Outlook can translate regulatory success into commercial results.

Announcement summary

(NASDAQ:OTLK) Outlook Therapeutics, Inc. announced the appointment of Greg DiPasquale as Chief Commercial Officer. Mr. DiPasquale joined Outlook in December 2025 as Head of Commercial for LYTENAVA™ and will now lead all commercial functions as the company prepares to make LYTENAVA, the first and only FDA-approved ophthalmic formulation of bevacizumab for wet age-related macular degeneration (wet AMD), available to eligible patients in the United States before the end of 2026. Mr. DiPasquale has over 30 years of commercial leadership experience, including nearly two decades in eye care and multiple retina product launches. LYTENAVA will be the fifth retina launch of his career, following BEOVU® at Novartis, EYLEA® prefilled syringe and EYLEA® HD at Regeneron, and the TRIESENCE® relaunch at Harrow. He most recently served as Senior Vice President and Head of Commercial at Harrow, and previously as National Business Director for EYLEA at Regeneron, where he led national sales for a portfolio generating approximately $6 billion in annual revenue. At Novartis, he was Vice President and Head of Sales for the Retina Division and led the October 2019 launch of BEOVU. He has also held senior commercial leadership roles at Bausch + Lomb, Carl Zeiss Vision, and Essilor USA. Bob Jahr, Chief Executive Officer of Outlook Therapeutics, stated that Mr. DiPasquale has already built the foundation of the company's commercial organization and that his leadership will be central to bringing LYTENAVA to physicians and patients. Mr. DiPasquale will lead commercialization teams including market access, commercial operations, marketing, sales, and reimbursement. He holds a Bachelor of Business Administration in Marketing and Human Resources from Ohio University and an Executive MBA from Kent State University, and serves as Executive in Residence and faculty lecturer at the Ohio University College of Business. LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) is an ophthalmic formulation of bevacizumab produced in the United States for the treatment of wet AMD and is the only ophthalmic formulation approved by the FDA in the United States. LYTENAVA is also the subject of a centralized Marketing Authorization granted by the European Commission in the EU and by the MHRA in the UK for the treatment of adults with wet AMD. In certain European Union Member States, LYTENAVA must receive pricing and reimbursement approval before it can be sold. Bevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant humanized IgG1 monoclonal antibody specific to human vascular endothelial growth factor (VEGF), binding all isoforms of VEGF-A and preventing interaction with receptors VEGFR-1 and VEGFR-2. LYTENAVA is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD). LYTENAVA is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to bevacizumab products or any ingredients in LYTENAVA. Intravitreal injections have been associated with endophthalmitis and retinal detachments, and increases in intraocular pressure have been noted post-injection (up to 60 minutes) while being treated with LYTENAVA. There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors. The most common adverse reactions (≥1%) reported in patients receiving LYTENAVA were conjunctival hemorrhage (4%), eye pain (2%), and vitreous floaters (2%). Outlook Therapeutics commenced commercial launch of LYTENAVA (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.

Disagree with this article?